Mylan Pharma Takes On Boehringer’s Mirapex Patent

Law360, New York (December 14, 2005, 12:00 AM EST) -- Mylan Pharmaceuticals Inc. is seeking to challenge German drug maker Boehringer Ingelheim International Gmbh for market share of Parkinson’s disease drug Mirapex. That challenge prompted a federal lawsuit in which Mylan will try to invalidate the drug’s patents.

Boehringer’s complaint, filed in conjunction with its Connecticut-based subsidiary, was brought in the U.S. District Court for the District of Delaware.

The lawsuit came on the heels of Mylan’s Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration, which seeks approval to manufacture and market...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.